In this study the investigators are aiming to treat patients with acute heart failure with or
without diabetes with Empagliflozin or placebo. Given the beneficial effects of Empagliflozin
on heart failure hospitalization in the EMPA-REG OUTCOME trial, the investigators do expect a
similar beneficial effect to be present in patients with acute heart failure. Acute heart
failure is a state of hydropic decompensation resulting in dyspnea and congestions, caused by
different etiologies of cardiac disease. Recompensation is reached by application of diuretic
drugs and fluid restriction.